- Home
- ANVS vs FSEA Comparison
ANVS vs FSEA Comparison
Compare ANVS & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- FSEA
- Stock Information
- Founded
- ANVS 2008
- FSEA 1890
- Country
- ANVS United States
- FSEA United States
- Employees
- ANVS N/A
- FSEA N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- FSEA Savings Institutions
- Sector
- ANVS Health Care
- FSEA Finance
- Exchange
- ANVS Nasdaq
- FSEA Nasdaq
- Market Cap
- ANVS 44.6M
- FSEA 52.8M
- IPO Year
- ANVS 2020
- FSEA N/A
- Fundamental
- Price
- ANVS $2.67
- FSEA $11.20
- Analyst Decision
- ANVS Strong Buy
- FSEA
- Analyst Count
- ANVS 4
- FSEA 0
- Target Price
- ANVS $18.00
- FSEA N/A
- AVG Volume (30 Days)
- ANVS 433.2K
- FSEA 3.4K
- Earning Date
- ANVS 08-14-2025
- FSEA 08-08-2025
- Dividend Yield
- ANVS N/A
- FSEA N/A
- EPS Growth
- ANVS N/A
- FSEA N/A
- EPS
- ANVS N/A
- FSEA 0.00
- Revenue
- ANVS N/A
- FSEA $16,196,000.00
- Revenue This Year
- ANVS N/A
- FSEA N/A
- Revenue Next Year
- ANVS N/A
- FSEA N/A
- P/E Ratio
- ANVS N/A
- FSEA $1,486.35
- Revenue Growth
- ANVS N/A
- FSEA 97.61
- 52 Week Low
- ANVS $1.11
- FSEA $8.90
- 52 Week High
- ANVS $13.91
- FSEA $11.80
- Technical
- Relative Strength Index (RSI)
- ANVS 57.27
- FSEA 47.47
- Support Level
- ANVS $2.63
- FSEA $11.22
- Resistance Level
- ANVS $2.97
- FSEA $11.35
- Average True Range (ATR)
- ANVS 0.25
- FSEA 0.09
- MACD
- ANVS 0.03
- FSEA -0.01
- Stochastic Oscillator
- ANVS 82.61
- FSEA 46.64
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.